CEVEC Pharmaceuticals, is a global solution provider of safe and efficient biopharmaceuticals with authentic human post translational modification patters. CEVEC’s platform expression technologies, CAP® and CAP-T®, are based on immortalized suspension cells derived from primary human amniocytes, designed for stable and transient protein production and achieve highest protein yields with authentic human glycosylation patterns. 

CEVEC has a high focus on research & development, production and marketing of its cell systems for protein and vaccine production accompanied by its development of selected “bio-better” and “bio-superior” candidates.
Powered by: